Tian Jihua, Zeng Xing, Zhu Junyu, Guan Wei, Hu Zhiquan, Yang Chunguang
Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
Transl Cancer Res. 2023 Feb 28;12(2):301-309. doi: 10.21037/tcr-22-1389. Epub 2023 Jan 29.
To compare the effectiveness of cytoreductive partial nephrectomy (CPN) and cytoreductive radical nephrectomy (CRN) in the treatment of metastatic T1-T2 renal cell carcinoma (RCC).
We obtained the clinical and pathological data of patients with metastatic T1-T2 RCC who underwent CPN or CRN from the Surveillance, Epidemiology, and End Results (SEER) database (https://seer.cancer.gov). Propensity score matching (PSM) was used to balance differences in characteristics between CPN and CRN cases. Kaplan-Meier survival analysis and univariate and multivariate Cox regression were used to assess the effect of partial nephrectomy (PN) versus radical nephrectomy (RN) on overall survival (OS) and cancer-specific survival (CSS).
After screening, 866 eligible cases were obtained. During the 1-107 months of follow-up, 500 patients died, 453 (90.6%) of whom died of RCC. The tumor size in the CRN group was significantly greater than that in the CPN group. Kaplan-Meier survival analysis showed that there was no significant difference in OS and CSS between the CPN group and the CRN group before and after matching. Univariate and multivariate Cox regression analysis found that the risk factors for OS were older age at diagnosis [hazard ratio (HR) =1.02, P=0.008], non-clear cell renal cell carcinoma (ccRCC) pathological type (HR =1.69, P=0.002), number of metastases ≥2 (HR =2.13, P<0.001), and regional lymph node involvement (HR =2.22, P=0.004), while the risk factors for CSS were non-ccRCC pathological type (HR =1.51, P=0.021) and the number of metastases ≥2 (HR =2.24, P <0.001).
CPN can provide similar oncologic outcomes as can CRN in T1-2M1 cases, and tumor metastatic burden is a major risk factor for survival in these patients with metastatic renal cell carcinoma (mRCC).
比较减瘤性部分肾切除术(CPN)和减瘤性根治性肾切除术(CRN)治疗转移性T1-T2期肾细胞癌(RCC)的疗效。
我们从监测、流行病学和最终结果(SEER)数据库(https://seer.cancer.gov)中获取了接受CPN或CRN治疗的转移性T1-T2期RCC患者的临床和病理数据。采用倾向评分匹配(PSM)来平衡CPN组和CRN组病例之间的特征差异。使用Kaplan-Meier生存分析以及单因素和多因素Cox回归来评估部分肾切除术(PN)与根治性肾切除术(RN)对总生存期(OS)和癌症特异性生存期(CSS)的影响。
经过筛选,共获得866例符合条件的病例。在1至107个月的随访期间,500例患者死亡,其中453例(90.6%)死于RCC。CRN组的肿瘤大小显著大于CPN组。Kaplan-Meier生存分析表明,匹配前后CPN组和CRN组的OS和CSS均无显著差异。单因素和多因素Cox回归分析发现,OS的危险因素为诊断时年龄较大[风险比(HR)=1.02,P=0.008]、非透明细胞肾细胞癌(ccRCC)病理类型(HR =1.69,P=0.002)、转移灶数量≥2个(HR =2.13,P<0.001)以及区域淋巴结受累(HR =2.22,P=0.004),而CSS的危险因素为非ccRCC病理类型(HR =1.51,P=0.021)和转移灶数量≥2个(HR =2.24,P <0.001)。
在T1-2M1病例中,CPN可提供与CRN相似的肿瘤学结局,并且肿瘤转移负担是这些转移性肾细胞癌(mRCC)患者生存的主要危险因素。